Clinical trial

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

NCT03693339

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Capmatinib Normalized identity: capmatinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-10-30

PhasePHASE2

Conditions

Cancerverified · MONDO: cancer

Lung Cancer Metastaticunresolved

MET Gene Mutationunresolved

Interventions

CapmatinibDRUG · verified · RxNorm: capmatinib

Sponsors & collaborators

Asan Medical Centerlead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03693339 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.